Fast dissolving antibody tablets for preventing vaginal HSV transmission

用于预防 HSV 阴道传播的快速溶解抗体片

基本信息

  • 批准号:
    10547476
  • 负责人:
  • 金额:
    $ 30.65万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary Despite immense efforts in educational and behavioral interventions to promote safer sexual practices, sexually transmitted infections (STIs) such as genital herpes remain highly prevalent, with an estimated 12% of people age 14-49 infected with HSV-2 in the United States. Unfortunately, there are no effective vaccines or microbicides for the majority of STIs, including HSV. An on-demand, fast-acting, safe, effective, and discreet vaginal microbicide would provide a powerful prevention tool to address gaps not addressed by behavioral and current pharmacologic interventions. Human monoclonal antibodies (mAb) delivered locally to mucosal surfaces offer exceptional promise, combining a long history of safety, anti-viral effectiveness, and unparalleled target specificity. Mucommune has been pioneering mAb technologies designed for mucosal applications, including muco-trapping mAbs that neutralizes and physically traps individual pathogens in mucus, based on carefully-tuned affinity between IgG-Fc and mucins. These “muco-trapping” mAbs can fully trap HSV particles in human cervicovaginal mucus (CVM) across the menstrual cycle and in CVM from women with diverse vaginal microflora, with ~10-fold greater potency than protection by neutralization alone. More importantly, trapping viruses in mucus with vaginally-dosed mAbs directly blocked transmission in a mouse vaginal Herpes model, in the absence of other immune protective functions. In this Phase I SBIR, we will build upon our work to formulate our pathogen-trapping mAb into fast dissolving Ab tablets (FDATs), which will rapidly disintegrate and disburse upon contact with CVM, providing rapid and potent immunoprotection. In Aim 1, we will incorporate muco-trapping mAbs against HSV into various FDAT formulations containing different types/ratios of excipients, binders and disintegrants. We will characterize the physical properties of the FDATs, measure the dissolution rates of FDATs in synthetic mucus and mixtures of fresh human CVM/semen, as well as verify the binding affinity of the mAb pre- post- FDAT formulation and dissolution. In Aim 2, we will evaluate our lead FDAT formulations from Aim 1 in a sheep vagina model to verify FDAT disintegration times, mAb pharmacokinetics and biodistribution, pharmacodynamics, and safety. Successful completion of these studies will enable us to identify a suitable FDAT formulation to advance into IND-enabling preclinical and clinical development, and provide the essential data for a Phase II proposal supporting development of shelf-stable FDAT that includes mAb cocktail consisting of both anti-HSV mAb and our lead contraceptive mAb (MM008), providing effective multipurpose protection against both vaginal Herpes transmission and pregnancy.
项目摘要 尽管在教育和行为干预方面做出了巨大努力,以促进更安全的性行为, 生殖器疱疹等性传播感染仍然非常普遍,估计 在美国,14-49岁的人中有12%感染了HSV-2。不幸的是,没有有效的 疫苗或杀微生物剂用于大多数性传播感染,包括单纯疱疹病毒。一种按需、快速、安全、有效、 谨慎的阴道杀微生物剂将提供一个强大的预防工具,以解决没有解决的差距, 行为和当前的药物干预。局部递送的人单克隆抗体(mAb) 粘膜表面提供了特殊的承诺,结合了长期的安全性,抗病毒有效性, 无与伦比的目标特异性。Mucommune一直是设计用于粘膜的mAb技术的先驱 应用,包括粘膜捕获mAb,其中和并物理捕获单个病原体, 粘液,基于IgG-Fc和粘蛋白之间的仔细调节的亲和力。这些“粘膜捕获”mAb可以完全 在整个月经周期中将HSV颗粒捕获在人宫颈阴道粘液(CVM)中, 具有多种阴道微生物区系的女性,其效力比单独中和的保护作用高约10倍。 更重要的是,用阴道给药的mAb在粘液中捕获病毒,直接阻断了病毒在阴道中的传播。 小鼠阴道疱疹模型,在没有其他免疫保护功能的情况下。在第一阶段SBIR中, 将在我们的工作基础上将我们的病原体捕获mAb配制成快速溶解的Ab片剂(FDAT), 在与CVM接触时,其将迅速崩解并分散, 免疫保护在目标1中,我们将针对HSV的粘膜捕获mAb并入各种FDAT中, 含有不同类型/比例的赋形剂、粘合剂和崩解剂的制剂。我们将描述 FDAT的物理性质,测量FDAT在合成粘液和FDAT的混合物中的溶解速率。 新鲜人CVM/精液,以及验证mAb前-后- FDAT制剂的结合亲和力, 解散在目标2中,我们将在绵羊阴道模型中评估目标1中的主要FDAT制剂,以验证 FDAT崩解时间、mAb药代动力学和生物分布、药效学和安全性。 成功完成这些研究后,我们便可找出合适的FDAT配方, IND支持临床前和临床开发,并为II期提案提供基本数据 支持开发货架稳定的FDAT,包括由抗HSV mAb和 我们领先的避孕mAb(MM 008),可针对两种阴道疱疹提供有效的多用途保护 传播和怀孕。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Keiichiro Kushiro其他文献

Keiichiro Kushiro的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Keiichiro Kushiro', 18)}}的其他基金

Highly Acidifying Intravaginal Rings with Lactobacillus Probiotics to Treat Bacterial Vaginosis
含乳酸菌益生菌的高度酸化阴道环可治疗细菌性阴道病
  • 批准号:
    10699458
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
User-based identification of preferred design features for MM008, a non-hormonal contraceptive vaginal ring
基于用户的非激素避孕阴道环 MM008 的首选设计特征识别
  • 批准号:
    10459077
  • 财政年份:
    2022
  • 资助金额:
    $ 30.65万
  • 项目类别:
Development of a qualified pharmacokinetic bioassay to support preclinical and clinical studies of MM-008, a non-hormonal contraceptive antibody
开发合格的药代动力学生物测定法以支持非激素避孕抗体 MM-008 的临床前和临床研究
  • 批准号:
    10459074
  • 财政年份:
    2022
  • 资助金额:
    $ 30.65万
  • 项目类别:
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV
胶囊阴道环,用于持续释放抗体,用于非激素避孕和阴道艾滋病毒保护
  • 批准号:
    9799170
  • 财政年份:
    2021
  • 资助金额:
    $ 30.65万
  • 项目类别:
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV
胶囊阴道环,用于持续释放抗体,用于非激素避孕和阴道艾滋病毒保护
  • 批准号:
    10381449
  • 财政年份:
    2021
  • 资助金额:
    $ 30.65万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 30.65万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了